Evidence map›Paper›PMID 39199649›Full record

ArticleCancers2024

Real-World Outcomes of Atezolizumab with Bevacizumab Treatment in Hepatocellular Carcinoma Patients: Effectiveness, Esophagogastroduodenoscopy Utilization and Bleeding Complications.

Cha Len Lee, Mark Freeman, Kelly W Burak, Gordon T Moffat, Conor D J O'Donnell, Philip Q Ding, Hanna Lyubetska, Brandon M Meyers, Vallerie Gordon, Ekaterina Kosyachkova and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Cha Len LeePrincess Margaret Cancer Center, University of Toronto, Toronto, ON M5G1Z5, Canada.ORCID 0000-0002-3919-7539
Mark FreemanTom Baker Cancer Center, University of Calgary, Calgary, AB T2N4N2, Canada.
Kelly W BurakLiver Unit, Divisions of Gastroenterology & Hepatology and Transplant Medicine, Departments of Medicine and Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N4N2, Canada.ORCID 0000-0002-6774-0754
Gordon T MoffatPrincess Margaret Cancer Center, University of Toronto, Toronto, ON M5G1Z5, Canada.
Conor D J O'DonnellJuravinski Cancer Center, Escarpment Cancer Research Institute, McMaster University, Hamilton, ON L8S4L8, Canada.
Philip Q DingTom Baker Cancer Center, University of Calgary, Calgary, AB T2N4N2, Canada.ORCID 0000-0002-0413-5485
Hanna LyubetskaCancerCare Manitoba, University of Manitoba, Winnipeg, MB R3A1R9, Canada.
Brandon M MeyersJuravinski Cancer Center, Escarpment Cancer Research Institute, McMaster University, Hamilton, ON L8S4L8, Canada.
Vallerie GordonCancerCare Manitoba, University of Manitoba, Winnipeg, MB R3A1R9, Canada.
Ekaterina KosyachkovaPrincess Margaret Cancer Center, University of Toronto, Toronto, ON M5G1Z5, Canada.
Roxana BucurPrincess Margaret Cancer Center, University of Toronto, Toronto, ON M5G1Z5, Canada.
Winson Y CheungTom Baker Cancer Center, University of Calgary, Calgary, AB T2N4N2, Canada.
Jennifer J KnoxPrincess Margaret Cancer Center, University of Toronto, Toronto, ON M5G1Z5, Canada.
Vincent C TamTom Baker Cancer Center, University of Calgary, Calgary, AB T2N4N2, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The IMbrave150 trial established atezolizumab with bevacizumab (A+B) as standard care for hepatocellular carcinoma (HCC), recommending an esophagogastroduodenoscopy (EGD) within 6 months of treatment initiation to prevent bleeding from esophagogastric varices. The necessity of mandatory EGD for all patients remains unclear. We retrospectively analyzed 112 HCC patients treated with A+B at five Canadian cancer centers from 1 July 2020 to 31 August 2022. A+B was the first-line therapy for 90% of patients, with median overall survival at 20.3 months and progression-free survival at 9.6 months. There was no survival difference between patients with bleeding and those without. Before A+B, 71% (n = 79) of patients underwent an EGD within 6 months, revealing varices in 41% (n = 32) and requiring intervention in 19% (n = 15). The overall bleeding rate was 15% (n = 17), with GI-specific bleeding occurring in 5% (n = 17). In the EGD group, GI-specific bleeding was 6% (n = 5) while in the non-EGD group, it was 3% (n = 1). Non-GI bleeding was observed in 10% (n = 11) of patients. Outcomes for HCC patients treated with A+B in Canada were comparable to IMbrave150. There was no increase in GI bleeding in patients without pre-treatment EGD, possibly supporting a selective EGD approach.

Indexed as

atezolizumabbevacizumabEGDGI bleedinghepatocellular carcinomavarices

Identifiers

PMID39199649
PMCPMC11352899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.